PBYI Valuation

Puma Biotechnology Inc

Add to Watchlist

Advanced Chart

3.400

-0.05(-1.449%)1D

Overview
Forecast
Valuation
Earnings

PBYI Relative Valuation

PBYI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PBYI is overvalued; if below, it's undervalued.

Historical Valuation

Puma Biotechnology Inc (PBYI) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.77 is considered Undervalued compared with the five-year average of -75.86. The fair price of Puma Biotechnology Inc (PBYI) is between 7.90 to 10.95 according to relative valuation methord. Compared to the current price of 3.40 USD , Puma Biotechnology Inc is Undervalued By 56.96%.

Relative Value

Fair Zone

7.90-10.95

Current Price：3.40

56.96%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.77

P/B

Median3y

4.48

Median5y

-46.32

18.41

FCF Yield

Median3y

8.16

Median5y

5.76

Competitors Valuation Multiple

The average P/S ratio for PBYI's competitors is 6.07, providing a benchmark for relative valuation. Puma Biotechnology Inc Corp (PBYI) exhibits a P/S ratio of 0.77, which is -87.29% above the industry average. Given its robust revenue growth of 5.12%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

PBYI.O

Puma Biotechnology Inc

0.77

Average P/S: 6.07

5.12%